Lepu Medical
Engaged in the R&D, production and sales of cardiovascular disease plant intervention diagnosis and treatment equipment and cardiovascular drugs.
Lepu Medical, founded in June, 1999 and headquartered in Beijing, is an enterprise engaged in the R&D, production and sales of cardiovascular drugs and cardiovascular disease plant interventional diagnosis and treatment equipment . The founder is Pu Zhongjie. Listed on the SZSE on October 30, 2009, the company's major shareholders are Luoyang Ship Material Research Institute, Pu Zhongjie and WP Medical Technologies, INC. Rivals that have direct and indirect competition with Lepu Medical include Peijia, Kintor, Aprea Therapeutics, Viela, etc.
Medtronic's world's first self expanding pulmonary valve was first-class recalled
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus
Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU
Upside foods, a cell meat enterprise, received US $400 million in financing, the highest single transaction in the industry
Lingfu biology, an experimental animal research service provider, completed a pre-A round of financing of more than 200 million yuan
Endoscope Developer Microlite Secures Tens of Mns of CNY in Angel Round
The funds will be used for the research and development of disposable endoscopes and other products, the construction of GMP (good manufacturing practice) workshops and the registration and certification of products.
May 11, 2022 11:46 PM
Hefei Tiangang immunopharmaceutical Co., Ltd., a tumor immunotherapy enterprise, completed a round of pre-A financing of hundreds of millions of yuan
State Affairs Office: revise and issue the negative list of market access (2021 version) before the end of the year to carry out the pilot of relaxing market access